Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation.

ISRN nephrology Pub Date : 2012-12-24 eCollection Date: 2013-01-01 DOI:10.5402/2013/184527

Dimitris Xydakis, Apostolos Papadogiannakis, Maria Sfakianaki, Konstantinos Kostakis, Konstantinos Stylianou, Ioannis Petrakis, Antonaki Ergini, Konstantinos Voskarides, Eugeneios Dafnis

{"title":"Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation.","authors":"Dimitris Xydakis, Apostolos Papadogiannakis, Maria Sfakianaki, Konstantinos Kostakis, Konstantinos Stylianou, Ioannis Petrakis, Antonaki Ergini, Konstantinos Voskarides, Eugeneios Dafnis","doi":"10.5402/2013/184527","DOIUrl":null,"url":null,"abstract":"<p><p>Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis. </p>","PeriodicalId":90192,"journal":{"name":"ISRN nephrology","volume":"2013 ","pages":"184527"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045428/pdf/","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5402/2013/184527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 16

Abstract

Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.

查看原文本刊更多论文

血液透析患者的残余肾功能:血管紧张素转换酶抑制剂在其保存中的作用。

残余肾功能(RRF)在血液透析患者的总体发病率和死亡率中起着重要作用。血管紧张素转换酶抑制剂(ACEi)在保护慢性蛋白尿肾病患者肾功能中的作用已得到充分证实。我们检验了依那普利(一种ACEi)减缓开始血液透析患者RRF下降速度的假设。进行了一项前瞻性、随机、开放标签的研究。42例患者被随机分为两组，一组接受依那普利治疗，另一组完全不接受治疗。我们的研究证明，依那普利对血液透析开始后至少12个月内开始透析的患者保留残余肾功能有显著作用。为了进一步研究ACEi对开始血液透析的患者的残余肾功能和发病率和死亡率的潜在长期影响，需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ISRN nephrology

自引率

0.00%

发文量